|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas.
|
28903316 |
2017 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
Atypical lipomatous tumor/well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) are characterized cytogenetically by a 12q13-15 amplification involving the mouse double minute 2 (MDM2) oncogene.
|
25132285 |
2015 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MDM2 and CDK4 genes are the main targets of chromosome 12 amplification in well-differentiated and dedifferentiated liposarcomas.
|
21910158 |
2011 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
Atypical lipomatous tumor/well-differentiated liposarcomas and dedifferentiated liposarcomas are characterized by the amplification of MDM2 and CDK4 genes.
|
17895748 |
2007 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MDM2 and CDK4 gene amplification levels, along with JUN amplification and copy alterations at 3q29, can be utilized for predicting outcome in patients with DDLS.
|
29153098 |
2017 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, MDM2 gene amplification, a diagnostic signature of well-differentiated/dedifferentiated liposarcoma (WDL/DL), was evaluated to address the recent observation that this gene is amplified within PL-like areas in DL.
|
22472959 |
2012 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
Such similarities in the clinical characteristics, morphology, genomic profile, and follow-up of peripheral UPS with MDM2 amplification and peripheral conventional DDLPS strongly suggest that peripheral UPS with MDM2 amplification are in fact DDLPS.
|
24525499 |
2014 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
Meta-analyses showed that the test of detecting MDM2 amplification by fluorescence in situ hybridization was accurate in differentiating atypical lipomatous tumor/well-differentiated liposarcoma/dedifferentiated liposarcoma from benign tumors (N = 971; sensitivity = 95%, 95% confidence interval [CI] 89-98; specificity = 100%, CI 89-100) or from other STS (N = 347; sensitivity = 99%, CI 72-100; specificity = 90%, CI 78-95); that the test of detecting SS18-SSX fusion by reverse transcription polymerase chain reaction (PCR) was accurate in differentiating synovial sarcoma from other STS (N = 532; sensitivity = 93%, CI 85-96; specificity = 99%, CI 96-100).
|
29709714 |
2018 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
MDM2 amplification is a diagnostic hallmark of ALT/WDLPS/DDLPS.
|
30887579 |
2019 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
MDM2 amplification was noted in 7/8 (88%) atypical lipomatous tumors/well-differentiated and 3/3 (100%) dedifferentiated liposarcomas, respectively, but not in four pleomorphic liposarcomas.
|
25446247 |
2014 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we present <i>in silico</i>, <i>in vitro</i>, and mouse xenograft studies that suggest that specifically targeting HDAC2 reduces MDM2 expression and has anti-tumor affects in DDLPS.
|
31620242 |
2019 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We recently evaluated a mesenteric mass initially diagnosed as dedifferentiated liposarcoma, largely due to the neoplasm's myxoid morphology and MDM2 expression by immunohistochemistry, from a 46-yr-old woman with a history of uterine low-grade endometrial stromal sarcoma (LG-ESS) with a JAZF1 rearrangement.
|
26444253 |
2015 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the well-differentiated and dedifferentiated liposarcomas, 100% showed amplification of MDM2.
|
18500263 |
2008 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MDM2 and HMGA2 genes are consistently amplified in well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) whereas CDK4 is frequently but not always amplified in these tumors.
|
19737942 |
2009 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finding of MDM2 and CDK4 iperexpression by immunohistochemistry confirmed the diagnosis of dedifferentiated liposarcoma.
|
16489442 |
2006 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
By contrast, mdm2 overexpression emerges as the most frequent abnormality in dedifferentiated liposarcoma (57 and 78 per cent of cases in well-differentiated and high-grade areas, respectively).
|
9071997 |
1997 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
In well-differentiated and dedifferentiated liposarcoma their clinical promise is associated with their ability to downregulate the MDM2 protein.
|
29789718 |
2018 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
FISH analysis on paraffin wax-embedded sections showed amplifications of MDM2 and CDK4 in seven of seven inflammatory MFHs and in seven of seven dedifferentiated liposarcomas.
|
15221942 |
2004 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
DDL share similar genetic abnormalities to WDL, with high-level amplifications of chromosome 12q14-15, including the MDM2 and CDK4 cell cycle oncogenes, and DDL harbor additional genetic changes, particularly coamplifications of 6q23 and 1p32.
|
26645460 |
2016 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ultrasound-guided fine-needle aspiration of a posterior neck dedifferentiated liposarcoma with MDM2 fluorescence in situ hybridization performed on a Pap-stained smear.
|
25132684 |
2015 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we investigate whether 'Fédération Nationale des Centres de Lutte Contre le Cancer' (FNCLCC) grade and MDM2 gene amplification levels have prognostic value in dedifferentiated liposarcoma in terms of local recurrence and disease-specific survival.
|
25059573 |
2015 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MDM2 and/or CDK4 protein overexpression and gene amplification are beneficial ancillary studies that can help establish the diagnosis of primary breast ALT/WDL and DDL, and effectively rule out the diagnoses of malignant phyllodes tumor and metaplastic breast carcinoma.
|
29372852 |
2018 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy.
|
19664496 |
2009 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, MDM2 staining and high-level MDM2 amplification were positive in all the DDLPS tested (28/28 and 20/20).
|
29309298 |
2018 |
|
Liposarcoma, Dedifferentiated
|
0.400 |
Biomarker
|
disease |
BEFREE |
MDM2 gene amplification normally present and used to aid in the diagnosis of retroperitoneal dedifferentiated liposarcoma was absent in this case.
|
24595525 |
2014 |